Trends in prescribing preferences (PPrefs) of US-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).

被引：0
|
作者：
Ryan, Charles J.
Kim, Won
Buettner, Arden
Britton, Susan Lynne
Lankford, Maria L.
Neely, Doug B.
Green, Mark R.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Xcenda, Tampa, FL USA
[4] Xcenda, Palm Harbor, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease
    Schmidt, Andrew
    Anton, Angelyn
    Shapiro, Julia
    Wong, Shirley
    Azad, Arun
    Kwan, Edmond
    Spain, Lavinia
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Joshua, Anthony M.
    Pook, David
    Gibbs, Peter
    Tran, Ben
    Weickhardt, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (01) : 36 - 42
  • [22] Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment
    Eliasson, Lina
    de Freitas, Hayley M.
    Dearden, Lindsay
    Calimlim, Brian
    Lloyd, Andrew J.
    CLINICAL THERAPEUTICS, 2017, 39 (04) : 723 - 737
  • [23] PSA response and cabazitaxel outcomes stratified by prior docetaxel PSA response in metastatic castrate-resistant prostate cancer (mCRPC).
    Wee, Christopher Eing
    Nizam, Amanda
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Chen, Xiaoying
    Maroli, Kimberly
    Martin, Allison
    Bonham, Amanda
    Pietro, Carolyn
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 119 - 119
  • [24] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [25] A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzal, Fatima
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Phillp M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Morris, M. J.
    Vogelzang, N. J.
    Sartor, O.
    Armour, A.
    Messmann, R.
    Groaning, M.
    Robarts, A.
    Tolcher, A. W.
    Gordon, M.
    Babiker, H. M.
    Kuo, P.
    Kearney, M.
    Jendrisak, A.
    Wang, Y.
    Landers, M.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).
    Ravi, Praful Kumar
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan D.
    Wong, Sophia
    Lorente, David Look
    Bianchini, Diletta
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
    Morris, Michael J.
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Armour, Alison A.
    Messmann, Richard Adam
    Groaning, Michael
    Robarts, Adam
    Tolcher, Anthony W.
    Gordon, Michael S.
    Babiker, Hani M.
    Kuo, Phillip
    Kearney, Megan
    Jendrisak, Adam
    Wang, Yipeng
    Landers, Mark Andrew
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Predictive Value of Early Prostate Specific Antigen (PSA) Response in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Treated With Post-Docetaxel Abiraterone
    Morley, Courtney
    Delahunty, Rachel
    Parente, Phillip
    Pezaro, Carmel
    Mant, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 130 - 130
12345